Vortioxetine for Health & Longevity

Created on 11/20/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Vortioxetine is a prescription antidepressant approved for adult major depression. Its clearest value is treating depression and lowering relapse risk, though most evidence comes from its makers and independent reviewers judged its quality low. Manufacturer-funded trials support faster thinking during depression; results outside it are mixed. Main costs are early nausea, dose-related sexual dysfunction, and low-sodium, bleeding and drug-combination warnings. Its brain-sharpening value in healthy aging remains unproven. (Full Review)

Protocol

Standard label regimen
10 mg once daily
Increased to 20 mg as tolerated; 5 mg for people who do not tolerate higher doses
European older-adult regimen
5 mg starting dose from age 65
Continuation for at least six months after symptoms resolve
Genetic polymorphisms
10 mg daily limit
For CYP2D6 poor metabolizers; ultrarapid metabolizers may need the upper dose range
Time to effect
Antidepressant benefit
6–8 weeks
Measured in registration trials
Processing speed
8 weeks
Assessed in cognitive trials
Steady drug levels
About two weeks
66-hour half-life supports a single daily dose

Benefits

Contraindications
  • MAOI use for psychiatric disorders or within 14 days of stopping one (no MAOI within 21 days after stopping vortioxetine)
  • Treatment with linezolid or intravenous methylene blue
  • Known hypersensitivity to vortioxetine
  • Children and adolescents aged 7–17 years
  • Untreated anatomically narrow eye drainage angles without an opening made in the iris
  • Unscreened or untreated bipolar disorder
Key Interactions
  • Other serotonergic drugs (SSRIs, SNRIs, triptans (migraine drugs), tricyclics (older antidepressants), tramadol, fentanyl, lithium, buspirone, amphetamines): higher serotonin syndrome risk
  • Strong CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine, quinidine): raise vortioxetine levels
  • Strong CYP inducers (drugs speeding up liver enzymes: rifampin, carbamazepine, phenytoin): lower vortioxetine levels
  • Antiplatelet drugs (which stop platelets clumping) and anticoagulants (aspirin, clopidogrel, heparin, warfarin): possible added bleeding risk
  • Over-the-counter NSAIDs (ibuprofen, naproxen, aspirin): added risk of gastrointestinal and other bleeding
  • Supplements: St. John's wort and tryptophan: raised serotonin syndrome risk
  • Diuretics (hydrochlorothiazide, furosemide): increased risk of low blood sodium
  • Ketoconazole and fluconazole: modest increases in vortioxetine exposure
  • Methadone urine screens: false-positive methadone results
Theoretical (inferred from mechanism)
  • 5-HTP (5-hydroxytryptophan) and SAMe (S-adenosylmethionine): possible serotonin syndrome
  • Dextromethorphan (over-the-counter cough suppressant): possible agitation, tremor or fever
  • High-dose fish oil, ginkgo and curcumin: possible increased bruising or bleeding, mainly relevant when anticoagulants or NSAIDs are also used
  • Cannabidiol: possible higher vortioxetine levels and more nausea

Risk & Side Effects

  • High: Nausea and other gastrointestinal effects
  • Medium: Sexual dysfunction; dizziness, itching and abnormal dreams
  • Low: Suicidal thoughts in young adults; discontinuation symptoms; hyponatremia; bleeding; serotonin syndrome; mania or hypomania; angle-closure glaucoma; hypersensitivity reactions; seizure, pancreatitis, smell loss and other postmarketing reports; pregnancy and newborn effects
  • Speculative: Rectal adenomas in female rats

Monitoring

Marker Target Why
Serum sodium 135–145 mmol/L Detects drug-induced low blood sodium
PHQ-9 score Below 5 Tracks depressive symptoms
DSST score No established target; change from the individual's own baseline Processing speed
CYP2D6 genotype No established target; metabolizer status recorded Poor metabolizers limited to 10 mg
INR Not specified in the ER Clotting check in people on warfarin
Serum osmolality Not specified in the ER Blood concentration check when sodium is low

Cadence: Symptom questionnaires at 2, 4 and 8 weeks, then every 3 months; sodium at baseline and 2–4 weeks in adults over 65 or on diuretics, and again after dose increases; processing-speed test at 8 weeks and every 6–12 months; sexual-function review at each visit; INR with warfarin when vortioxetine is started, dose-adjusted or stopped

Qualitative Assessment

  • Mood, motivation and interest in usual activities
  • Mental sharpness, focus and word-finding
  • Nausea, appetite and bowel habits in the first weeks
  • Sleep quality and dream intensity
  • Sexual desire, arousal and orgasm
  • Energy levels and emotional range, including any sense of emotional flatness